Anti-parasitic compounds from Streptomyces sp. strains isolated from Mediterranean sponges.
Actinomycetes are prolific producers of pharmacologically important compounds accounting for about 70% of the naturally derived antibiotics that are currently in clinical use. In this study, we report on the isolation of Streptomyces sp. strains from Mediterranean sponges, on their secondary metabolite production and on their screening for anti-infective activities. Bioassay-guided isolation and purification yielded three previously known compounds namely, cyclic depsipeptide valinomycin, indolocarbazole alkaloid staurosporine and butenolide. This is the first report of the isolation of valinomycin from a marine source. These compounds exhibited novel anti-parasitic activities specifically against Leishmania major (valinomycin IC(50) < 0.11 microM; staurosporine IC(50) 5.30 microM) and Trypanosoma brucei brucei (valinomycin IC(50) 0.0032 microM; staurosporine IC(50) 0.022 microM; butenolide IC(50) 31.77 microM). These results underscore the potential of marine actinomycetes to produce bioactive compounds as well as the re-evaluation of previously known compounds for novel anti-infective activities.
Pimentel-Elardo
Sheila Marie
SM
Julius-von-Sachs Institute for Biological Sciences, University of Würzburg, Würzburg, Germany. sheila-marie.elardo@mail.uni-wuerzburg.de
Kozytska
Svitlana
S
Bugni
Tim S
TS
Ireland
Chris M
CM
Moll
Heidrun
H
Hentschel
Ute
U
D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D000818:Animals; D018320:Leishmania major / Q000187:drug effects; D009682:Magnetic Resonance Spectroscopy; D011161:Porifera / Q000382:microbiology*; D019311:Staurosporine / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology; D013302:Streptomyces / Q000378:metabolism*; D014344:Trypanocidal Agents / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology; D014346:Trypanosoma brucei brucei / Q000187:drug effects; D014634:Valinomycin / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology
D014344:Trypanocidal Agents; D014634:Valinomycin; C004511:butenolide; D019311:Staurosporine; D015107:4-Butyrolactone
Antonie Van Leeuwenhoek. 2005 Jan;87(1):11-8
15726286
Appl Environ Microbiol. 2009 Nov;75(21):6820-6
19749071
Antonie Van Leeuwenhoek. 2005 Jan;87(1):43-8
15726290
J Nat Prod. 2001 May;64(5):664-7
11374972
J Nat Prod. 2000 Nov;63(11):1570-2
11087613
Curr Opin Microbiol. 2006 Jun;9(3):245-51
16675289
Nat Chem Biol. 2006 Dec;2(12):666-73
17108984
Environ Microbiol. 2005 Apr;7(4):509-18
15816928
Appl Environ Microbiol. 2002 Oct;68(10):5005-11
12324350
Antonie Van Leeuwenhoek. 2007 Nov;92(4):405-16
17566868
Int J Syst Evol Microbiol. 2008 Mar;58(Pt 3):628-32
18319468
J Nat Prod. 2002 Mar;65(3):295-8
11908968
Int J Cancer. 1998 Jul 3;77(1):64-9
9639395
Acta Trop. 1993 Dec;55(4):257-61
8147282
Antonie Van Leeuwenhoek. 2006 Aug;90(2):159-69
16871424
Antimicrob Agents Chemother. 2006 Jul;50(7):2439-47
16801424
Trends Microbiol. 2007 Nov;15(11):491-9
17997312
Appl Environ Microbiol. 2001 Jan;67(1):434-44
11133476
Int J Syst Evol Microbiol. 2009 Jun;59(Pt 6):1433-7
19502329
J Nat Prod. 2003 Oct;66(10):1299-301
14575426
Antonie Van Leeuwenhoek. 2005 Jan;87(1):29-36
15726288
Int J Antimicrob Agents. 2007 Jun;29(6):637-42
17353113